NHS England and NHS Improvement seeks patients and carers to work with the Quality Surveillance Team
A message from NHS England & NHS Improvement:
Did you know that you, as a patient or carer, you can join a team who work to help maintain and improve congenital gynae anomalies services in our hospitals?
NHS England and NHS Improvement is calling for patients and carers who have used congenital gynae anomalies services to join the peer review programme along with clinicians, nurses, psychologists, other health care professionals and managers to ensure high quality care is being delivered and to accelerate the spread of good practice across the NHS. This would entail the following:
- Attend a half day training event
- Half day preparation before the review visit (reading documents)
- Undertake at least one peer review visit at a hospital site in which you or your family member did not receive care
- Visit day usually 8:45 am start and finish at 4:00 pm
- Approximately one and a half hours post visit to check accuracy of report electronically via email.
All reasonable travel and carers support costs to attend the training day and peer review visits can be reclaimed or train tickets can be booked through the Review Support Team, in advance, if necessary. Overnight accommodation can also be booked and paid for by the Quality Surveillance Programme in advance of the review visit, if travelling distances permits. Service users are also eligible to claim an honorarium payment of £150.00 for attending a peer review visit.
If you think this is for you then please complete the application form and we will be in contact to arrange for you to attend one of our training sessions. By attending the training event, this will enable you to make an informed decision as to whether to continue with the process to become a reviewer; it does not commit you to further involvement. In the meantime, if you require further information please do not hesitate to contact lisacunnington@nhs.net or England.qstreviewsupport@nhs.net
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...